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 Abstract 
 Background: Enhanced oxidative stress has been associ-
ated with atherosclerosis and coronary artery disease (CAD). 
However, the predictive value of circulating oxidative stress 
biomarkers for cardiovascular events (CE) in patients with 
CAD has remained poorly understood. 
 Aim: To assess the prognostic signifi cance of reactive oxygen 
metabolites, estimated as index of oxidative stress in serum sam-
ples by means of a commercial kit (ROMs, Diacron, Italy) on 
the rate of mortality and major adverse CE (MACE) in CAD. 
 Methods: A study of 93 consecutive patients with angio-
graphically documented CAD (75 males, age: 68 ± 10 years, 
mean ± SD) was made during a mean follow-up of 66 months 
until the occurrence of one of the following CE: cardiac and 
all cause death, non-fatal myocardial infarction and coronary 
revascularization [percutaneous transluminal coronary angio-
plasty (PTCA) and coronary artery bypass grafting (CABG)]. 
Patient data were retrospectively collected from the Institute ’ s 
electronic databank that saves demographic, clinical, instru-
mental and follow-up data of all patients admitted to our 
department. 
 Results: The Kaplan-Meier survival estimates showed a 
signifi cantly worst outcome in patients presenting elevated 
ROM level ( > 75th percentile, corresponding to 481 AU) (log 
rank = 11, 7.5, 5.1; p < 0.001, p < 0.01, p < 0.05 for cardiac and 
all cause death and MACEs, respectively). In a multivariate 
Cox regression model, elevated oxidative stress remained a 
signifi cant predictor of cardiac and all cause death [hazard 
ratio (HR) 3.9, 95 % confi dence interval, 95 % (CI) 1.4 – 11.1, 
p = 0.01; HR = 2.6, 95 % CI 1.1 – 6.2, p = 0.02) and MACE 
(HR = 1.8, 95 % CI 1.1 – 3.1, p = 0.03)]. 
 Conclusions: The estimation of ROMs may represent an 
additional prognostic tool in the assessment of CE in CAD 
patients. 
 Keywords:  atherosclerosis;  cardiovascular events;  coronary 
artery disease;  follow-up;  oxidative stress. 
 Introduction 
 There is general agreement on the fact that oxidative stress 
represents a relevant determinant involved in the pathogen-
esis and development of a variety of chronic and degenerative 
diseases, including aging, cancer and atherosclerosis. In par-
ticular, an enhanced oxidative stress status plays a signifi cant 
role in the onset and progression of atherosclerotic damage 
 (1, 2) . However, the predictive value of oxidative stress bio-
markers for cardiac events in patients with coronary artery 
disease (CAD) is still poorly understood  (3) . 
 Recently, a simple method to estimate reactive oxygen 
metabolites in serum samples by means of a commercial kit 
(ROMs, Diacron, Italy) has been developed  (4, 5) , giving 
reliable results in terms of assessment of the oxidative stress 
status and monitoring of antioxidant treatment strategies  (6, 
7) . In particular, we previously evidenced that elevated levels 
of ROMs are associated with cardiovascular risk factors and 
CAD, and found ROMs as independent predictors of death in 
patients with cardiovascular disease  (8 – 11) . 
 Thus, in the present study we tested the hypothesis that 
elevated levels of ROMs, evaluated as index of the oxidative 
stress status, may predict mortality and major adverse cardio-
vascular events (MACE) in patients with CAD. 
 Materials and methods 
 Subjects 
 Subjects selected to participate in the study were 93 consecutive in-
patients (75 males, age: 68 ± 10 years, mean ± SD) with angiographi-
cally documented CAD, admitted to the Coronary Care Unit of the 
CNR-Clinical Physiology Institute in Pisa. 
 Patient data were collected from the Institute ’ s electronic databank 
that saves demographic, clinical, instrumental and 10-year follow-
up data of all consecutive patients admitted to our department from 
January 2001  (12) . Information on left ventricular function was obtained 
by echocardiography or by left ventricular angiography. Database in-
formation on smoking habit, family history of ischemic heart disease, 
arterial hypertension (systolic blood pressure > 140 mm Hg and/or dia-
stolic pressure  > 90 mm Hg or by the use of antihypertensive medica-
tion), diabetes (fasting plasma glucose  > 126 mg/dL corresponding to 
7 mmol/L or use of antidiabetic treatment), obesity (body mass index 
 > 30 kg/m 2 ), and dyslipidemia (defi ned when total cholesterol concen-
tration was  ≥ 200 mg/dL corresponding to 5.18 mmol/L, or triglyceride 
concentration  ≥ 150 mg/dL corresponding to 1.695 mmol/L, or current 
use of lipid-lowering drugs) were coded in a dichotomized fashion. 
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 Smoking habit was coded by grouping patients into no-smokers 
(those who had never smoked), ex-smokers (who had quit smoking for 
at least 6 months) and current smokers. Medical therapy included ACE 
inhibitors, beta-blockers, lipid-lowering agents, diuretics, and aspirin. 
No patient was receiving vitamins and/or antioxidant therapies. 
 Informed consent was obtained from each patient. The authors 
confi rm that they have complied with the World Medical Association 
Declaration of Helsinki regarding ethical conduct of research invol-
ving human subjects. 
 Follow-up 
 Follow-up data were obtained from at least one of the following four 
sources: review of the patient ’ s record, telephone interview con-
ducted by trained personnel, personal communication with the pa-
tient ’ s physician or medical visit at the outpatient clinic. The clinical 
events recorded during the follow-up and analyzed for the prediction 
of MACE were cardiac and total mortality, non-fatal myocardial in-
farction, and coronary revascularization [percutaneous transluminal 
coronary angioplasty (PTCA) and coronary artery bypass grafting 
(CABG)]. The cause of death was derived from medical records or 
death certifi cates. The defi nition of cardiac death required the docu-
mentation of either signifi cant arrhythmias, or cardiac arrest, or death 
attributable to congestive heart failure, or myocardial infarction in 
the absence of any other precipitating factor. Non-cardiac causes of 
death included two stroke, three malignancies, two infections, one 
acute abdomen and one death during surgical intervention. The dia-
gnosis of myocardial infarction was based on the documentation of 
persistent electrocardiographic ST segment changes, or new Q-wave 
development, associated with biomarker increase. 
 Blood sampling and storage of samples 
 All subjects were studied in the morning and in a fasting state. Blood 
samples were drawn from the left antecubital vein, kept on ice and 
centrifuged within 15 min after blood collection at 2500  g for 15 
min at 4 ° C. Then, serum samples were immediately stored at  – 80 ° C 
for  < 2 weeks before subsequent analysis. 
 Analytical method 
 The oxidative stress status was estimated in serum samples by using 
the d-ROMs test (Diacron, Italy), as we previously described in de-
tail  (5, 13) . In brief, the d-ROMs test is based on the ability of transi-
tion metal to catalyse in the presence of peroxides with generation 
of free radicals that are trapped by an alchilamine. The reaction of 
alchilamine yields a coloured radical detectable at 505 nm. The re-
sults were expressed as arbitrary units (AU). 
 As we previously reported, the limit of quantifi cation for the ROM 
test, defi ned as the concentration corresponding to the mean value of 
10 determinations of the zero calibrator  ± 2 SD, resulted 40 AU  (5) . 
The standard calibration curves for the d-ROMs test are linear up to 
475 AU, with correlation coeffi cients  > 0.99. Samples with different 
concentrations are evaluated to estimate within- and between-run coef-
fi cients of variation (CVs). Intra- and inter-assay coeffi cients of varia-
tion resulted always lower that 5 % for ROMs. Recovery obtained after 
addition of different amounts of known concentration to six different 
aliquots of two serum samples ranges between 97 % and 105 %  (5) . 
 Statistical analysis 
 Data were expressed as the mean ± SEM. Statistical analysis included 
Student ’ s t-test,  χ 2 -test, and ANOVA analysis and Scheffe ’ s test using 
the statistical package Statview, version 5.0.1 (SAS Institute, Abacus 
Concept, Inc., Berkeley, CA, USA). Cumulative event rates were es-
timated by Kaplan-Meier survival curves and probability values de-
termined with the log-rank test. For survival analysis, only one event 
was considered in each patient. Statistical analysis also included Cox 
proportional hazard models to determine independent predictors of 
CE. A p < 0.05 was considered statistically signifi cant. 
 Results 
 Demographic and clinical characteristics of patients are sum-
marized in Table  1 . 
 ROMs were slightly skewed among the study participants, 
ranging from 157 AU to 883 AU (median 378.5 AU; skewness 
0.9) (Figure  1 ). Patients with multivessel disease had higher 
levels of ROMs compared to one vessel disease (434 ± 19 vs. 
362 ± 19 AU, p ≤ 0.01). Higher levels of ROMs were also asso-
ciated with female sex (463 ± 39 vs. 392 ± 15, p < 0.05). 
 Patients were followed for a period of 66 ± 28 months, with 
occurrence of 66 events. Specifi cally, 24 (26 % ) patients died 
(15 cardiac death), 6 (9 % ) had a non-fatal MI and 36 under-
went revascularization (22 PTCA and 14 CABG). 
 The cumulative survival rates free of events on the basis 
of Kaplan-Meier analysis for cardiac and all cause death and 
MACE are shown in Figure  2 . The Kaplan-Meier survival 
estimates showed a signifi cantly worst outcome in patients 
presenting elevated concentration of ROMs ( > 75th percen-
tile, corresponding to 481 AU) for all the endpoints consid-
ered (log rank = 11, p < 0.001; 7.5, p < 0.01; 5.1, p < 0.05, for 
cardiac and all cause death and MACE, respectively). 
 The signifi cant univariate effect of high levels of oxidative 
stress was seen as considering cardiac and total death (hazard 
ratio, HR = 4.7, confi dence interval, CI 1.7 – 13.1, p < 0.01 and 
HR = 3, CI 1.3 – 6.6, p < 0.01, respectively) (Table  2 ). The other 
parameters associated with cardiac and all cause death at the 
univariate analysis are also shown in Table 2. In the multivari-
ate Cox regression model, elevated oxidative stress showed an 
independent effect on cardiac (HR = 3.9, CI 1.4 – 11.1, p ≤ 0.01) 
and total death (HR = 2.6, CI 1.1 – 6.2, p < 0.05) (Table 2). 
 The elevated concentration of ROMs, among all the vari-
ables considered, resulted the only determinant signifi cantly 
associated with the occurrence of a MACE (Table  3 ). 
 Discussion 
 This study demonstrated that high levels of ROMs, as index 
of the oxidative stress status, can serve as an independent and 
signifi cant predictor for CE in CAD patients. 
 Oxidative stress represents a recognized determinant in the 
onset and progression of endothelial dysfunction and atheroma 
formation  (1) . Indeed, elevated oxidative stress may cause 
marked cellular and tissue damage, inducing events such as 
lipid peroxidation, oxidation of proteins and DNA, and reduc-
ing NO production  (1) . However, most of the evidence linking 
oxidative stress to CAD is obtained in in vitro system, or in 
experimental studies on animals, or by observational human 
studies  (3) . Accordingly, disorders closely associated to the 
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atherosclerotic process, such as diabetes, hypertension, and 
dyslipidemia, have all been associated with elevated levels of 
different oxidative stress biomarkers  (5, 7, 8, 13) . Moreover, 
we and others have demonstrated that different oxidative 
stress parameters -including d-ROMs and biomarkers of lipid 
peroxidation and DNA damage- are related to increased risk 
for cardiovascular disease and correlated with the number of 
cardiovascular risk factors  (9, 10, 13 – 16) . 
 The extent of the relationship between oxidative stress and 
atherosclerosis and cardiovascular (CV) risk factors rose the 
hypothesis that antioxidant supplementation could reduce the 
global burden related to CAD  (17) . However, expectations 
about clinical benefi ts from the administration of antioxidants 
were hampered, although several biases can be assumed 
regarding the negative results of such clinical intervention 
trials  (17) . 
 Other than diet differences, age, stage of disease as well 
as sex and lifestyle, there are many other points to consider. 
 Table 1  Baseline characteristics of the study population. 
n  93
Age, years  68 ± 10
Age ( > 69 years, 50th percentile)  44 (47)
Males  75 (81)
Hypertension  55 (59)
Type 2 diabetes  32 (34)
Dyslipidemia  50 (54)
Smoking habit  34 (36.5)
  Current smokers  7 (7.5)
  Ex-smokers  27 (29)
Ejection fraction,  %  50.2 ± 12.9
Ejection fraction  < 40 %  20 (21)
Coronary angiography
  One-vessel disease  37 (40)
  Multi-vessel disease  56 (60)
Prior myocardial infarction  50 (54)
ROMs, AU 406 ± 137
ROMs ( > 481 AU, 75th percentile)  23 (25)
 Data presented are mean value ± SD or number ( % ) of patients. 
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 Figure 2  Kaplan-Meier survival curves according to oxidative 
stress (levels  > 75 % percentile) considering cardiac death (A), all 
cause death (B) and MACE (panel C) as end points. 
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 Figure 1  Distribution of ROM levels in the CAD patient 
population. 
Generally, patient selection of these trials was based on the 
hypothesis that all patients could benefi t from antioxidant 
supplementation, and not on biochemical evidence of oxida-
tive stress  (17) . Conversely, it is important to consider the pre-
existing oxidative stress status of each patient, as antioxidant 
supplementation could not be effective in patients in whom 
there was no increase in oxidative stress. In addition, moni-
toring of the trend in levels of oxidative stress biomarkers, 
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including d-ROMs, must also be included during the antioxi-
dant treatment. 
 Vitamin E has been used in mostly clinical trials, but other 
antioxidants, or combination of more antioxidants, may be 
more effective  (17) . The dosage and duration of supplementa-
tion must be also considered. The presence of specifi c genetic 
variants of key enzymes in the detoxifi cation of reactive oxy-
gen species may be an important factor in the susceptibility of 
an individual, and should be evaluated in future studies. 
 The treatment of patients with other drugs can be another 
confounding factor, because different drugs may potentially 
affect the oxidative stress status, because some molecules 
retain antioxidant properties (e.g., calcium channel blockers). 
However, in the present study we did not observe any signifi -
cant relationship between d-ROMs concentration and specifi c 
pharmacological therapies (data not shown). 
 Table 2  Cox predictive model for cardiac and total death. 
Univariate analysis Multivariate analysis
HR (95 % CI) p-Value HR (95 % CI) p-Value
Cardiac death
  Hydroperoxides ( > 481 AU) 4.7 (1.7 – 13.1) 0.003 3.9 (1.4 – 11.1) 0.01
  Age ( > 69 years, 50th percentile) 3.5 (1.1 – 10.8) 0.03 2.8 (1 – 9.1) 0.09
  LVEF ( < 40 % ) 5.1 (1.9 – 14.2) 0.0016 4.2 (1.5 – 12) 0.006
  Diabetes 3.3 (1.2 – 9.3) 0.03 2.6 (1 – 7.5) 0.07
  Dyslipidemia 0.5 (0.5 – 1.3) ns  – 
  Gender 1.1 (0.5 – 3.8) ns  – 
  Hypertension 1.4 (0.6 – 4.2) ns  – 
  Smoking habit 1.6 (0.8 – 4.3) ns  – 
  Prior myocardial infarction 2 (0.8 – 5.7) ns  – 
Total death
  Hydroperoxides ( > 481 AU) 3 (1.3 – 6.6) 0.009 2.6 (1.1 – 6.2) 0.02
  Age ( > 69 years, 50th percentile) 2.5 (1.1 – 5.8) 0.035 2.5 (1 – 5.9) 0.04
  LVEF ( < 40 % ) 3.2 (1.4 – 7.3) 0.005 2.3 (1.0 – 5.2) 0.05
  Diabetes 2.6 (1.2 – 5.8) 0.02 2.9 (1.2 – 6.8) 0.014
  Dyslipidemia 0.3 (0.5 – 1) 0.01 0.33 (0.5 – 0.9) 0.015
  Gender 1.2 (0.6 – 3.4) ns  – 
  Hypertension 1.4 (0.6 – 3.3) ns  – 
  Smoking habit 1.5 (0.7 – 3.4) ns  – 
  Prior myocardial infarction 1.6 (0.8 – 3.7) ns  – 
 LVEF, left ventricular ejection fraction; HR, hazard ratio; CI, confi dence interval; ns, not signifi cant. 
 Table 3  Cox predictive model for MACEs. 
Univariate analysis
HR (95 % CI) p-Value
Hydroperoxides ( > 481 AU) 1.8 (1.1 – 3.1) 0.03
Age ( > 69 years, 50th percentile) 1.2 (0.8 – 2) ns
LVEF ( < 40 % ) 1.1 (0.8 – 1.9) ns
Diabetes 1.3 (0.9 – 2.1) ns
Dyslipidemia 1 (0.8 – 1.6) ns
Gender 1.3 (0.8 – 2.3) ns
Hypertension 0.8 (0.6 – 1.4) ns
Smoking habit 1.3 (0.9 – 2.1) ns
Prior myocardial infarction 1.2 (0.8 – 2) ns
 LVEF, left ventricular ejection fraction; HR, hazard ratio; CI, confi -
dence interval; ns, not signifi cant. 
 Although at the moment the clinical use of antioxidant 
supplementation is not recommended, the evaluation of their 
potential benefi cial effects require more efforts. There is a 
large body of observational (epidemiological, case-control, 
or prospective and retrospective studies) data on the dietary 
antioxidant intake linked to prevention of CV risk factors and 
onset and progression of atherosclerosis  (17) . In this context, 
the evolution of natural dietary patterns with relevant effec-
tiveness represents a challenge for the future, as these com-
pounds may be crucial complementary treatment options for 
subjects at risk for CV disease. 
 The predictive value for cardiac events in CAD by using oxi-
dative stress biomarkers, including oxidized-LDL, myeloper-
oxidase (MPO), and lipid and protein peroxidation measures, 
has been recently reviewed  (3) . Majority of studies suggested 
a role for oxidative stress biomarkers in the prediction of CE, 
although some evidences lack to fi nd any association  (3) . 
 The observed differences may be due to the use of differ-
ent parameters, heterogeneity of design and analysis and lack 
of the standardization method. The different approaches used 
to determine oxidative stress biomarkers in body fl uids (for 
example gas chromatography/mass spectrometry, gas chro-
matography tandem mass spectrometry, or liquid chroma-
tography tandem mass spectrometry, radioimmunoassay and 
enzyme immunoassay for F2-isoprostane) may induce great 
variation in the level measured  (18 – 21) . In this context, we 
paid particular attention to the preanalytical phase (see Blood 
sampling and storage of samples in the Materials and methods 
section). In fact, sample handling is extremely important to 
estimate oxidative stress in vivo and may represent another 
important source for confl icting results. Samples left at room 
temperature or which have been freeze-thawed can undergo 
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auto-oxidation  (22) . For example, MPO levels may be greatly 
affected by this factor, because leucocytes continue to release 
MPO in samples not maintained on ice  (3) . 
 The ROMs test, used for this study, is able to estimate 
hydroperoxides and other oxidizing agents in the sample, 
evidence of an early oxidative damage  (23) . These bio-
markers have been previously found associated to various 
condition related to an elevated oxidative stress. In particu-
lar, ROMs have been previously found correlated with the 
presence and number of CV risk, the presence of CAD, and 
associated with infl ammatory parameters in healthy subjects 
and CAD patients by us and others  (5, 7, 10, 13, 24) . In the 
present study, this biomarker appears also correlated with the 
severity of CAD, being higher in patients with multivessel 
disease. 
 We found that baseline ROM levels resulted signifi cantly 
higher in women than in men. However, it is important to 
consider the advanced age of our patients, and the fact that 
mostly women were in a postmenopausal status, when the 
oxidative stress status has been observed higher in women 
than in men both in healthy and CAD patients  (8, 9, 25) . 
 The present study had some limitations. We performed 
only baseline measurements of oxidative stress, without 
evaluating whether the levels of these biomarkers changed 
over time. Moreover, our sample size was small, although the 
long follow-up time allows observing a consistent number of 
events. However, as such, the fi ndings need to be confi rmed 
in a larger sample size and prospectively designed studies. 
Nonetheless, these potential limitations do not invalidate our 
observations that are descriptors of a relevant pathophysio-
logic mechanism. It is also important to remind that, although 
the relatively low number of patients enrolled may represent a 
limitation, the importance of our results is reinforced by strict 
criteria used to select a well-defi ned and characterized subject 
population. 
 In conclusion, our study indicates a major role of elevated 
ROMs in the prediction of cardiac events, suggesting that the 
estimate of oxidative stress might represent an additive sen-
sitive biomarker of prognostic stratifi cation in patients with 
known CAD. 
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